close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

ImmunoGen, Inc. - Common Stock (NQ:IMGN)

N/A UNCHANGED
Last Price Updated: 4:00 PM EST, Feb 9, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about ImmunoGen, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
News headline image
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From ImmunoGen Inc.
Via Business Wire
News headline image
ImmunoGen Reports Recent Progress and Third Quarter 2021 Financial Results
From ImmunoGen Inc.
Via Business Wire
News headline image
ImmunoGen Announces Conference Call to Discuss Its Third Quarter 2021 Operating Results
From ImmunoGen Inc.
Via Business Wire
News headline image
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From ImmunoGen Inc.
Via Business Wire
News headline image
ImmunoGen Appoints Helen M. Thackray, MD to its Board of Directors
From ImmunoGen Inc.
Via Business Wire
News headline image
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From ImmunoGen Inc.
Via Business Wire
News headline image
ImmunoGen Reports Recent Progress and Second Quarter 2021 Financial Results
From ImmunoGen Inc.
Via Business Wire
News headline image
ImmunoGen Announces Conference Call to Discuss Its Second Quarter 2021 Operating Results
From ImmunoGen Inc.
Via Business Wire
News headline image
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From ImmunoGen Inc.
Via Business Wire
News headline image
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From ImmunoGen Inc.
Via Business Wire
News headline image
ImmunoGen Announces Webcast of Presentation at Upcoming Jefferies Virtual Healthcare Conference
From ImmunoGen Inc.
Via Business Wire
News headline image
ImmunoGen Announces Mature Data from FORWARD II Study Evaluating Mirvetuximab Soravtansine in Combination with Avastin® in Recurrent Ovarian Cancer, Regardless of Platinum Status
From ImmunoGen Inc.
Via Business Wire
News headline image
ImmunoGen Reports Recent Progress and First Quarter 2021 Financial Results
From ImmunoGen Inc.
Via Business Wire
News headline image
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From ImmunoGen Inc.
Via Business Wire
News headline image
ImmunoGen Announces Conference Call to Discuss Its First Quarter 2021 Operating Results
From ImmunoGen Inc.
Via Business Wire
News headline image
ImmunoGen Presents Preclinical Data on IMGC936 at the AACR Virtual Annual Meeting
From ImmunoGen Inc.
Via Business Wire
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today